Research Topics
| A C CollierSummaryAffiliation: University of Washington Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Antiretroviral-drug resistance among patients recently infected with HIVSusan J Little
Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
N Engl J Med 347:385-94. 2002..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapyChristina M Marra
Harborview Medical Center, University of Washington, Seattle, WA, USA
BMC Infect Dis 7:37. 2007....- A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve peopleJeffrey T Schouten
Department of Surgery, University of Washington, Seattle, USA
BMC Infect Dis 6:28. 2006..The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss... - CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?Keri N Althoff
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
AIDS Res Ther 7:45. 2010..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed... - A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapyAnn C Collier
University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
J Infect Dis 192:1398-406. 2005..Adherence to antiretroviral therapy is difficult, and methods to increase it are needed... 
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier
University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
HIV Clin Trials 9:91-102. 2008....- Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trialA C Collier
School of Medicine, University of Washington, Seattle, WA 98104, USA
JAMA 285:1592-601. 2001..Data in selected non-HIV-infected patients requiring blood transfusion have suggested clinical benefit with leukocyte-reduced red blood cells (RBCs)... - Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDSM M Berrey
Department of Medicine, University of Washington, Seattle, WA, USA
J Infect Dis 183:1466-75. 2001..Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and reduced progression to AIDS... - Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and bloodR W Coombs
Department of Laboratory Medicine, University of Washington, School of Medicine, Seattle 98195 7110, USA
J Infect Dis 177:320-30. 1998.... - Why don't patients and physicians talk about end-of-life care? Barriers to communication for patients with acquired immunodeficiency syndrome and their primary care cliniciansJ R Curtis
Department of Medicine, University of Washington, Seattle 98104 2499, USA
Arch Intern Med 160:1690-6. 2000..Interventions to improve this communication have generally been unsuccessful, suggesting that important barriers to this communication must exist... - Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapyC M Marra
Department of Neurology, School of Medicine, University of Washington, Seattle, USA
Neurology 60:1388-90. 2003..001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01)... - Low atazanavir concentrations in cerebrospinal fluidBrookie M Best
Skaggs School of Pharmacy andPharmaceutical Sciences, School of Medicine, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, MC 0719, La Jolla, CA 92093 0719, USA
AIDS 23:83-7. 2009..The objective of this study was to determine atazanavir penetration into cerebrospinal fluid (CSF)... - Are there benefits to starting antiretroviral therapy during primary HIV infection? Conclusions from the Seattle Primary Infection Cohort vary by control groupJ D Stekler
Department of Medicine, University of Washington, Seattle, WA, USA
Int J STD AIDS 23:201-6. 2012..Randomized trials are needed to address benefits of cART during PHI... - A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group)J M Agosti
Department of Medicine, University of Washington, Seattle
AIDS Res Hum Retroviruses 8:581-7. 1992..These cytokines alone do not appear to be of benefit, nor do they appear to hasten the progression of HIV infection... - Cerebrospinal fluid treponemal antibodies in untreated early syphilisC M Marra
Department of Medicine, University of Washington, Seattle
Arch Neurol 52:68-72. 1995..Nonreactive CSF treponemal tests may help to exclude a diagnosis of neurosyphilis in patients with early syphilis... - Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complexA C Collier
Department of Medicine, University of Washington, Seattle, USA
J Acquir Immune Defic Syndr Hum Retrovirol 10:150-6. 1995..Additional studies that achieve higher CD4-IgG concentrations are necessary to evaluate the antiviral activity of this compound... - Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasmaJashvant D Unadkat
Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
Nucl Med Biol 35:911-7. 2008..Therefore, we developed a rapid solid-phase extraction (SPE) method to separate, and then quantify, verapamil and its radiolabeled metabolites in plasma... - Lower genitourinary tract sources of seminal HIVRobert W Coombs
Department of Laboratory Medicine, University of Washington, Seattle, WA 98104 2499, USA
J Acquir Immune Defic Syndr 41:430-8. 2006..To investigate genital tract sources of HIV-1, we conducted extensive genitourinary sampling of 23 seropositive men without urethritis who shed HIV in their seminal plasma... - Abacavir hypersensitivity reaction in primary HIV infectionJoanne Stekler
Division of Allergy and Infectious Diseases, University of Washington, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104, USA
AIDS 20:1269-74. 2006..To evaluate risk factors associated with the abacavir hypersensitivity reaction during primary HIV infection (PHI)... - Effect of early versus deferred antiretroviral therapy for HIV on survivalMari M Kitahata
University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
N Engl J Med 360:1815-26. 2009..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain... - HIV dynamics in seminal plasma during primary HIV infectionJoanne Stekler
Department of Medicine, University of Washington, Seattle, Washington 98104, USA
AIDS Res Hum Retroviruses 24:1269-74. 2008..Incorporating seminal plasma HIV levels into future mathematical models may increase the accuracy of these models... - Primary HIV InfectionJoanne Stekler
Department of Medicine, Harborview Medical Center, Seattle, WA 98104, USA
Curr HIV/AIDS Rep 1:68-73. 2004..Immunomodulators and vaccines are also under study as adjuvant therapy for treatment of primary HIV infection... - Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomographyLucy Sasongko
Department of Pharmaceutics, Division of Nuclear Medicine, University of Washington, Seattle, WA 98195-7610, USA
Clin Pharmacol Ther 77:503-14. 2005..Our method for imaging P-gp activity can be used to identify multidrug-resistant tumors or to determine the contribution of P-gp polymorphism, inhibition, or induction to interindividual variability in drug response... - Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humansMark Muzi
Department of Radiology, University of Washington, Seattle, Washington 98195 6004, USA
J Nucl Med 50:1267-75. 2009..Here we extend the initial noncompartmental analysis of these data and apply compartmental modeling to these human verapamil imaging studies... - Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responsesYi Liu
Department of Microbiology, University of Washington School of Medicine, Seattle, Washington 98195 8070, USA
J Infect Dis 200:1825-33. 2009..However, some studies have shown preferential or similar targeting of variable versus conserved epitopes during primary infection... - Screening for acute HIV infection: lessons learnedJoanne Stekler
Department of Medicine, University of Washington, Seattle, WA, USA
Clin Infect Dis 44:459-61. 2007..We present cases to illustrate unusual instances of acute HIV screening, which include "window period" testing and the discovery of low-level HIV RNA... - Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 diseaseUma Malhotra
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
J Infect Dis 189:515-9. 2004..These findings indicate that Fas coexpression on T cells, in addition to plasma HIV-1 RNA levels and CD4+ T cell counts, may predict virologic outcome... - Primary HIV infection education: knowledge and attitudes of HIV-negative men who have sex with men attending a public health sexually transmitted disease clinicJoanne Stekler
Division of Allergy and Infectious Diseases and Center for AIDS Research, University of Washington, Seattle, WA 98104, USA
J Acquir Immune Defic Syndr 42:123-6. 2006..Until more individuals with PHI seek evaluation, the public health impact of RNA testing is likely to be small... - Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human dataPeng Hsiao
School of Pharmacy, Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA
J Pharmacol Exp Ther 317:704-10. 2006..This is the first time that an in vivo CsA EC(50) of P-gp inhibition at the rat BBB has been determined and the magnitude of such inhibition was compared between the rat and the human BBB at the same blood CsA concentration... - Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotypeWarren L Dinges
Vaccine and Infectious Disease Institute, Statistical Center for HIV Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Virol 84:4461-8. 2010..These data suggest that vaccine immunogens should contain only conserved regions of HIV-1... - The attitudes of patients with advanced AIDS toward use of the medical futility rationale in decisions to forego mechanical ventilationJ R Curtis
Department of Medicine, University of Washington, Seattle, USA
Arch Intern Med 160:1597-601. 2000..The medical futility rationale asserts that physicians need not offer their patients therapies that have zero or close to zero probability of success. The rationale is controversial, but it is used in practice... - Selection on the human immunodeficiency virus type 1 proteome following primary infectionYi Liu
Department of Microbiology, University of Washington School of Medicine, Seattle, WA 98195-8070, USA
J Virol 80:9519-29. 2006..Hence, a majority of the amino acids undergoing selection in this subject appeared to result from fitness-balanced CTL selection, confirming CTLs as a dominant selective force in HIV-1 infection... - Abnormal antibody responses in patients with persistent generalized lymphadenopathyH D Ochs
Department of Pediatrics, School of Medicine, University of Washington, Seattle 98195
J Clin Immunol 8:57-63. 1988..Yet despite obvious immunologic impairment five of the seven men have remained clinically stable over a 3-year follow-up period... - Evaluation of cerebrospinal fluid in Southeast Asian refugees with reactive serologic tests for syphilisD Buchwald
Department of Medicine, Harborview Medical Center, University of Washington School of Medicine, Seattle, USA
West J Med 165:289-93. 1996.... - Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B virusesYi Liu
Department of Microbiology, University of Washington School of Medicine, Seattle, Washington 98195 8070, USA
Virology 374:229-33. 2008.... - Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virusTae Wook Chun
Laboratory of Immunoregulation, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
J Infect Dis 195:1762-4. 2007..6 months. It is projected that it will take up to 7.7 years of continuous therapy to completely eliminate latently infected resting CD4+ T cells in infected individuals who initiate antiviral therapy early in HIV infection... - Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infectionAndrew J Leigh Brown
University of Edinburgh, Edinburgh, Scotland
J Virol 78:2242-6. 2004..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection... - Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infectionCraig W Hendrix
Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Acquir Immune Defic Syndr 37:1253-62. 2004..Overall, however, the average change in viral load across all patients was +0.03 log10 HIV RNA. Given these results, AMD3100 is not being further developed for ARV therapy, but development continues for stem cell mobilization... - Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba
School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
AIDS 19:145-52. 2005..To evaluate fosamprenavir/lopinavir (LPV)/ritonavir (RTV), fosamprenavir/RTV, or LPV/RTV in antiretroviral treatment-experienced patients. Lack of drug interaction data prompted a pharmacokinetic substudy to minimize subject risk... - Clinical validation of the NeuroScreenRonald J Ellis
Department of Neurosciences, UCSD AntiViral Research Center and HIV Neurobehavioral Research Center, University of California, San Diego, California 92103, USA
J Neurovirol 11:503-11. 2005..However, because it yields substantial numbers of false positives and negatives, the NeuroScreen may be less useful in evaluating individual patients... - Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapyRonald J Bosch
Center for Biostatistics in AIDS Research, Harvard University School of Public Health, Boston, MA 02115, USA
J Acquir Immune Defic Syndr 44:268-77. 2007..To examine pretreatment factors associated with longer term (144 weeks) responses to antiretroviral therapy (ART)... - AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristicsMarlene Smurzynski
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
HIV Clin Trials 9:269-82. 2008..We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy... - Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl
AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
AIDS 21:325-33. 2007..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens... - Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceLin Liu
University of California San Diego, La Jolla, California 92093 0679, USA
AIDS 22:835-9. 2008..We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance... - Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemScott Letendre
University of California, San Diego, 150 W Washington St, San Diego, CA 92103, USA
Arch Neurol 65:65-70. 2008..To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lower cerebrospinal fluid (CSF) viral load... - The prevalence and incidence of neurocognitive impairment in the HAART eraKevin R Robertson
Department of Neurology, UNC, Chapel Hill, North Carolina 27599, USA
AIDS 21:1915-21. 2007..The effects of HAART on neurological disease are less well understood. The aim of this study was to assess the prevalence and incidence of neurocognitive impairment in individuals who initiated HAART as part of an AIDS clinical trial... - Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)Pablo Tebas
Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
J Acquir Immune Defic Syndr 45:193-200. 2007..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication... - A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus diseaseMargaret A Fischl
Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
J Infect Dis 188:625-34. 2003..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity... - Clinical features of acute retroviral syndrome differ by route of infection but not by gender and agePhilippe Vanhems
Laboratoire d épidémiologie et de santé publique, and INSERM Unit 271, Faculte de Medecine, Universite Claude Bernard, et Hôpital Edouard Herriot, Lyon, France
J Acquir Immune Defic Syndr 31:318-21. 2002..52%, p=.01). Genital ulcerations were present only in cases of sexual exposure to HIV. Injecting drug users had or reported symptoms associated with the ARS less frequently than persons acquiring HIV via sexual transmission... - Lack of interaction between atazanavir and lansoprazoleBradley W Kosel
AIDS 19:637-8. 2005 - The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous systemScott L Letendre
University of California, 150 W Washington St, San Diego, CA 92103, USA
J Neuroimmune Pharmacol 2:120-7. 2007..Some of these drugs, such as serotonin reuptake inhibitors (SRIs) and HMG-CoA reductase inhibitors (statins), may do so by reducing HIV replication in the CNS and are already widely used by HIV-infected individuals...
Research Grants
- UW Clinical HIV Integrated Research ProgramAnn Collier; Fiscal Year: 2007..administrative component: ..